Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases

Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases: Epidemiological Data on Smoking and Preclinical and Clinical Data on Nicotine provides a comprehensive summary of the epidemiological data on smoking and several neurological disorders, including Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Tourette's syndrome, schizophrenia, anxiety, depression and ADHD, as well as preclinical and clinical data on the effects of nicotine. Despite the obvious and undisputed harmful nature of smoking, evidence suggests that some tobacco and tobacco smoke-derived constituents may offer neuroprotective effects, possibly in combinations, rather than individually. This unprecedented book describes the complex relationships between smoking and neurological disease and the bioactive compounds found in tobacco. It provides a comprehensive review of nicotine and other compounds found in tobacco plant, with scientific evidence of neuroprotective and anti-inflammatory effects that may act in conjunction with nicotine to exert neuroprotective effects observed in smokers. By presenting findings beyond harmful cigarette smoke effects, attention can be drawn to individual compounds of tobacco that may serve as inspiration for further therapy development. - Presents the first comprehensive, tabulated summary of literature on the epidemiological data on smoking and neurological disease - Includes preclinical and clinical data on nicotine in neurological diseases and mechanisms of action of nicotine in neuroprotection - Features a comprehensive summary of non-nicotine smoke constituents with potentially neuroprotective and anti-inflammatory properties - Discusses Multiple Sclerosis, Alzheimer's disease, Parkinson's Disease, Schizophrenia, Depression, ADHD, Anxiety and Tourette's Syndrome in the context of smoking and nicotine

Dr. Veljkovic is Manager - Study Management at Phillip Morris International in Neuchatel, Switzerland. Her research group is responsible for in vivo studies designed to further characterize the exact role of the cigarette smoke in initiation and development of lung pathologies (lung cancer, COPD) and CVD. She has nine years of experience in the tobacco industry, with a focus on inhalation toxicology and modeling of smoking-related diseases (lung cancer, chronic obstructive pulmonary disease) engaging systems toxicology approaches. With a thorough understanding of nicotine-related toxicity in animal models, Dr. Veljkovic and her team have prepared a number of internal strategic documents that required an extensive literature review about effects of nicotine and non-nicotine tobacco constituents in different diseases including neurological and neurodegenerative diseases. She holds BSc, MSc and PhD degrees in molecular biology and physiology.